Healthcare Realty Trust Inc (HR) Stock News

Pomerantz LLP is investigating potential securities fraud at Aether Holdings (ATHR), following a July 2025 short report by BMF Reports alleging fake filings, insider enrichment, lock-up violations, and undisclosed dealings. The allegations included concerns about a subsidiary acquisition with minimal business fundamentals. Aether's stock fell 23.95% on the report's publication.

A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) in the U.S. District Court for the District of Delaware, alleging that the company and its executives made false or misleading statements regarding revenue visibility. The company significantly reduced its FY 2027 revenue guidance from $545-$559 million to $510-$520 million on March 30, 2026, citing weaker pharmaceutical-marketing commitments and reduced visibility in its Network Solutions segment—risks that were not disclosed during the December 8, 2025 earnings call. The stock fell 21-28% following the revised outlook.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies. Phreesia Inc. faces allegations of misrepresenting growth projections, Sportradar Group AG is accused of working with black-market gambling operators while claiming compliance, Commvault Systems Inc. allegedly failed to properly account for sales type impacts on ARR growth, and Veritone Inc. is charged with revenue misclassification and deficient internal controls. Investors have until mid-July 2026 to file lead plaintiff motions.

Rosen Law Firm is notifying investors in Phreesia, Inc., Babcock & Wilcox Enterprises, Inc., and TruBridge, Inc. of ongoing securities class action lawsuits. Phreesia investors have until July 13, 2026 to serve as lead plaintiff. The lawsuit alleges Phreesia made false statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Phreesia, Inc. The lawsuit alleges that defendants made false and misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in the Network Solutions segment. The lead plaintiff deadline is July 13, 2026.

A class action lawsuit has been filed against Phreesia, Inc. (NYSE:PHR) for allegedly making false and misleading statements regarding its financial performance. The company failed to disclose slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. On March 30, 2026, Phreesia reduced its FY 2027 revenue guidance by $35-49 million to $510-520 million, citing weaker pharmaceutical-marketing commitments that had not been mentioned during the December 2025 earnings call. The stock fell 21-28% following the revised outlook. Investors who purchased shares between May 8, 2025, and March 30, 2026, can participate in the lawsuit with a deadline of July 13, 2026, to apply as lead plaintiff.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Phreesia Inc., Sportradar Group AG, Commvault Systems Inc., and Veritone Inc. Investors have until mid-July 2026 to file lead plaintiff motions. The complaints allege various forms of misrepresentation including false growth projections, undisclosed compliance violations, misleading revenue guidance, and accounting irregularities.

HR Tech 2026 conference (October 20-22 in Las Vegas) unveiled its agenda featuring sessions on AI implementation, skills development, and workforce transformation. Leading HR and talent executives from major companies including Amsted Industries, Cloudflare, IFF, Lumen, Sanofi, and TIAA will share practical strategies on job architecture, AI adoption, internal mobility, and HR technology readiness.

Vallourec has signed a Memorandum of Understanding with Ultra Corpotech Pvt Ltd to deploy its VAM® threading capabilities in India. The partnership aims to establish localized production of premium tubular solutions for Oilfield Services customers, with implementation planned for late 2026 and commissioning expected in early 2027. This reflects the broader shift of manufacturing activities from North America to the Eastern Hemisphere.

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.

DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against companies including Graphic Packaging Holding Company, Immutep Limited, and Phreesia, Inc. The lawsuits allege materially false and misleading statements regarding inventory management, clinical trial prospects, and growth outlook. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the announced deadlines in July 2026.

Rosen Law Firm is notifying Phreesia, Inc. (NYSE: PHR) investors who purchased stock between May 8, 2025 and March 30, 2026 about a securities class action lawsuit. The firm alleges that Phreesia made false or misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors have until July 13, 2026 to serve as lead plaintiff.

The Law Offices of Frank R. Cruz announced a securities fraud class action lawsuit against Phreesia Inc., alleging the company made false statements about its growth outlook and revenue projections between May 2025 and March 2026. The lawsuit claims Phreesia misrepresented the reliability of its pharmaceutical marketing commitments as a growth driver for its Network Solutions segment, putting its 2027 revenue targets at risk. Investors who suffered losses have until July 13, 2026 to participate as lead plaintiffs.

The DJS Law Group has filed a class action lawsuit against Phreesia, Inc. (NYSE: PHR) for securities law violations under the Securities Exchange Act of 1934. The lawsuit alleges that Phreesia made false and misleading statements regarding its pharmaceutical marketing commitments as a growth engine for its Network Solutions segment while knowing of industry uncertainty that would impact revenue guidance. The class period spans May 8, 2025 to March 30, 2026, with a deadline of July 13, 2026 for shareholders to join the case.

DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.

DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.

Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Phreesia Inc. for alleged securities fraud. The company allegedly misrepresented its revenue growth outlook and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing its stock to plummet 26.6% to $8.38 per share. Investors who purchased shares between May 8, 2025 and March 30, 2026 can file a lead plaintiff motion by July 13, 2026.

Rosen Law Firm has filed securities class action lawsuits against Phreesia Inc., Zoetis Inc., and ChampionX Corporation on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made false or misleading statements regarding business conditions, including slowing demand and reduced visibility in key revenue streams.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Phreesia, Inc. (PHR), where investors who purchased stock between May 8, 2025 and March 30, 2026 may be entitled to compensation. The lawsuit alleges Phreesia made false statements about slowing demand and reduced visibility in key revenue streams, particularly in its Network Solutions segment. Additional class actions are mentioned for Veritone, Inc. (VERI) and Stellantis N.V. (STLA). The lead plaintiff deadline for the Phreesia case is July 13, 2026.

Phreesia Inc. faces a securities fraud class action lawsuit after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Shareholders who purchased stock between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

TORONTO , May 28, 2026 /CNW/ - Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSXV: UFC ) ("Urbanfund" or the "Company"), confirmed today that the Company has filed its financial statements for the three months ended March 31, 2026 (the "Consolidated Financial Statements") and corresponding Management's Discussion and Analysis ("MD&A"). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange ("TSX-V") under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund's focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company's assets are located in Toronto, Brampton, Belleville, Kitchener and London, Ontario, Quebec City and Montreal, Quebec and Dartmouth, Nova Scotia. Operational Highlights Part of Urbanfund's strength is its ability to attract partners with proven track records with both residential and commercial development expertise. Urbanfund continues to build alliances with its strategic partners: 1040 Martin Grove Road, Toronto – During the three months ended March 31, 2026, two commercial units were sold for sales proceeds of $778,732 (March 31, 2025, two commercial units for $841,776). To date, the Company's capital contribution of $1,870,000 has been fully returned, and an additional profit distribution of $822,545 has been received to date, of which $154,000 was received subsequent to the quarter end. 270-330 Esna Park Drive, Markham - During the three months ended March 31, 2026, four commercial units were sold for sales proceeds of $901,952 (March 31, 2025 – four commercial units for $691,991). To date, the company has received $1,462,521 of distribution, of which $382,427 was received subsequent to the quarter end.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 have until July 13, 2026 to file a lead plaintiff motion.

The Schall Law Firm is seeking investors who purchased Phreesia, Inc. securities between May 8, 2025 and March 30, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its long-term growth outlook and fiscal year 2027 projections, particularly regarding pharmaceutical marketing commitments as a growth driver for its Network Solutions segment. Investors who suffered losses are encouraged to contact the firm before July 13, 2026.

Robbins LLP has filed a class action lawsuit against Phreesia, Inc. on behalf of investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misled investors regarding the sustainability of growth in its Network Solutions business and fiscal 2027 revenue outlook. The company failed to disclose weakening pharmaceutical marketing commitments and reduced visibility into future spending. On March 30, 2026, Phreesia lowered its fiscal 2027 revenue guidance from $545-$559 million to $510-$520 million, causing the stock to plunge approximately 27% in a single day.

A securities fraud class action lawsuit has been filed against Phreesia Inc. after the company announced significantly lowered revenue growth projections for fiscal 2027 on March 30, 2026, citing macroeconomic factors and weaker pharmaceutical marketing commitments. The stock fell 26.6% to $8.38 per share following the announcement. Investors who purchased shares between May 8, 2025 and March 30, 2026 may seek lead plaintiff status by July 13, 2026.

A class action lawsuit has been filed against Phreesia Inc. on behalf of investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misrepresented its revenue growth projections and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing the stock to fall 26.6% to $8.38 per share. Investors have until July 13, 2026 to file a lead plaintiff motion.

A class action lawsuit has been filed against Phreesia Inc. on behalf of shareholders who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia misrepresented its revenue growth projections and minimized risks in its Network Solutions segment. On March 30, 2026, Phreesia announced significantly lowered fiscal 2027 revenue projections, causing the stock to fall 26.6% to $8.38 per share. Investors have until July 13, 2026 to file a lead plaintiff motion.

Rosen Law Firm has filed a class action lawsuit on behalf of Phreesia, Inc. (NYSE: PHR) investors who purchased stock between May 8, 2025 and March 30, 2026. The lawsuit alleges that Phreesia made false and misleading statements regarding slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is July 13, 2026.

Glancy Prongay Wolke & Rotter LLP announced a securities fraud investigation into Phreesia Inc. following the company's announcement on March 30, 2026 of significantly lowered revenue growth projections for fiscal 2027. The announcement cited macroeconomic factors and weaker pharmaceutical marketing commitments. Phreesia's stock fell 26.6% to $8.38 per share on March 31, 2026, prompting the law firm to urge affected shareholders to contact them about potential recovery claims.